As of August 29, 2026, the three largest insider holders of BHVN are John W Childs (Director, 5.69Mn shares), John W Childs (Director, 5.65Mn shares), John W Childs (Director, 4.10Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John W Childs | Director | 0 | 5,653,904 | 5,653,904 | 46.1% | 17 Nov, 2025 |
| 2 | Vlad Coric | Chief Executive Officer | 3,347,362 | 833,120 | 4,180,482 | 34.0% | 07 Jan, 2026 |
| 3 | Gregory Bailey | Director | 2,020,071 | 0 | 2,020,071 | 16.5% | 17 Nov, 2025 |
| 4 | Matthew Buten | Chief Financial Officer | 195,652 | 0 | 195,652 | 1.6% | 07 Jan, 2026 |
| 5 | Kimberly Gentile | Svp, Clinical Operations | 99,557 | 0 | 99,557 | 0.8% | 07 Jan, 2026 |
| 6 | George C. Clark | Vp, Chief Accounting Officer | 66,978 | 0 | 66,978 | 0.5% | 07 Jan, 2026 |
| 7 | Kishan Mehta | Director | 5,320 | 17,342 | 22,662 | 0.2% | 19 Mar, 2026 |
| 8 | Michael Thomas Heffernan | Director | 15,178 | 0 | 15,178 | 0.1% | 12 Oct, 2022 |
| 9 | Robert J Hugin | Director | 12,959 | 0 | 12,959 | 0.1% | 12 Oct, 2022 |
| 10 | Bruce Car | Chief Scientific Officer | 7,715 | 0 | 7,715 | 0.1% | 07 Jan, 2026 |
| 11 | Irina Antonijevic | Director | 2,535 | 0 | 2,535 | 0.0% | 29 Dec, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 28 Apr, 2026 | John W Childs | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 28 Apr, 2026 | Robert J Hugin | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 28 Apr, 2026 | Julia P Gregory | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 28 Apr, 2026 | Michael Thomas Heffernan | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 28 Apr, 2026 | Gregory Bailey | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 28 Apr, 2026 | Kishan Mehta | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 28 Apr, 2026 | Irina Antonijevic | Director | Acquired A | 68,693 | $0.00 | $0 | 68,693 | Direct |
| 17 Mar, 2026 | Kishan Mehta | Director | Disposed G | 17,342 | $0.00 | $0 | 5,320 | Direct |
| 17 Mar, 2026 | Kishan Mehta | Director | Disposed G | 17,342 | $0.00 | $0 | 5,320 | Direct |
| 17 Mar, 2026 | Kishan Mehta | Director | Disposed G | 17,342 | $0.00 | $0 | 5,320 | Direct |
| 17 Mar, 2026 | Kishan Mehta | Director | Disposed G | 17,342 | $0.00 | $0 | 5,320 | Direct |
| 17 Mar, 2026 | Kishan Mehta | Director | Acquired G | 17,342 | $0.00 | $0 | 17,342 | Indirect |
| 17 Mar, 2026 | Kishan Mehta | Director | Acquired G | 17,342 | $0.00 | $0 | 17,342 | Indirect |
| 17 Mar, 2026 | Kishan Mehta | Director | Acquired G | 17,342 | $0.00 | $0 | 17,342 | Indirect |
| 17 Mar, 2026 | Kishan Mehta | Director | Acquired G | 17,342 | $0.00 | $0 | 17,342 | Indirect |
| 27 Feb, 2026 | Bruce Car | Chief Scientific Officer | Acquired A | 175,000 | $0.00 | $0 | 175,000 | Direct |
| 27 Feb, 2026 | Matthew Buten | Chief Financial Officer | Acquired A | 175,000 | $0.00 | $0 | 175,000 | Direct |
| 27 Feb, 2026 | Kimberly Gentile | Svp, Clinical Operations | Acquired A | 175,000 | $0.00 | $0 | 175,000 | Direct |
| 27 Feb, 2026 | Kimberly Gentile | Svp, Clinical Operations | Acquired A | 175,000 | $0.00 | $0 | 175,000 | Direct |
| 27 Feb, 2026 | George C. Clark | Vp, Chief Accounting Officer | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |